Laura Evangelista’s Post

We are seeing a proliferation of isotopes for radioligand therapy beyond Lutetium-177 (in pioneering RLTs Lutathera and Pluvicto), with growing focus on Actinium-225 and Lead-212 in particular thanks to their alpha-emitting properties and earlier efforts behind Astatine-211, Copper-67 and Terbium-161, among others. And yet there is unsustainable crowding around just a few targets. Most notably, there are 28 assets pursuing PSMA (Pluvicto's target) and another 10 assets pursuing SSTR2 (Lutathera's target) in an industry pipeline of ~100 RLT programs. How many of these assets can reasonably be expected to be commercially viable and deliver meaningfully superior clinical benefit vs the first-to-market RLTs in the same indications? Only a handful and these will almost certainly leverage next-gen radioisotopes such as 212Pb and 225Ac that bring unique advantages over beta emitters such as 177Lu. Would "returns" for patients and investors be better if we focused R&D spend and effort on the most differentiated emerging programs, and invested more robustly across a broader range of targets? In my view we need more urgency and more resources behind novel targets in Oncology. This is the only way to extend the power of RLTs, as soon as possible, to more patients beyond those suffering from prostate cancer and rare neuroendocrine tumors. Data source: Oppenheimer & Co.

Anche quest’anno il nostro ospedale si è tinto di rosa, grazie al sorriso delle oltre 130 donne che, affrontando il percorso oncologico in Humanitas, danno vita a #SorrisiInRosa. A inaugurare l’edizione 2024 un evento con Gerry Scotti e il Direttore del settimanale Gente Umberto Brindani oltre allo svelamento della mostra fotografica con foto e racconti delle nuove testimonial, avvolte nella sciarpa rosa simbolo del progetto. Con la nostra Breast Unit siamo in prima linea per diffondere la cultura della prevenzione senologica. Dalla diagnosi alla cura, quello del tumore al seno è un percorso di squadra: grazie a chirurghi, oncologi, radiologi, radioterapisti, infermieri, psicologi e ricercatori che ogni giorno lavorano per aprire nuove strade alla cura delle patologie femminili. Special thanks to Luisa Morniroli e Cristina Barberis Negra ideatrici e cuori pulsanti di #SorrisiInRosa in collaborazione con i nostri senologi. Corrado Tinterri Alberto Testori Daniela Bernardi Marta Scorsetti Gjeloshi Margarita armando santoro Walter Bruno Gianmarco Monterosso Monica Florianello

🚨 Calling all EANM Members! 🚨 Join us at the EANM Members' Assembly—your key to staying informed about the vital work of our volunteers, elected representatives, and financial matters, as well as the association’s ongoing activities. This is your opportunity to engage, ask questions, and gain insights into the strategic planning of the EANM in a collaborative, transparent setting. 🗓️ Sunday, October 20 I 13:15–14:45 CEST 📍 Hall F I Level 2 Do not miss this chance to get involved and shape the future of the EANM!